Search
AMD Invests $20 Million in AI Drug Development Pioneer Absci
2025-01-09
AMD has announced a $20 million investment in Absci, a pioneering company in AI-driven drug development. Through this collaboration, AMD and Absci will integrate AMD's Instinct accelerators and ROCm software to bolster Absci's AI-powered drug discovery initiatives, with a particular focus on antibody design models. This strategic move marks AMD's inaugural foray into the life sciences sector, leveraging its advanced AI chips to revolutionize the drug development process.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
